Literature DB >> 11478906

Differential roles of developmentally distinct SNAP-25 isoforms in the neurotransmitter release process.

E B Puffer1, R B Lomneth, H K Sarkar, B R Singh.   

Abstract

The role of SNAP-25 (synaptosomal associated protein of 25 kDa) isotypes in the neurotransmitter release process was examined by varying their relative abundance during PC12 cell differentiation induced by nerve growth factor (NGF). Norepinephrine release by NGF-differentiated PC12 cells is more sensitive to type A botulinum toxin (BoNT/A) than by nondifferentiated cells, while both differentiated and nondifferentiated PC12 cells are equally sensitive to type E botulinum toxin (BoNT/E). The differential sensitivity to BoNT/A corresponds to an altered susceptibility of SNAP-25 isotypes to BoNT/A cleavage in vitro, whereas both isotypes are equally vulnerable to cleavage by BoNT/E. Using recombinant SNAP-25 preparations, we show that BoNT/A cleaves SNAP-25b (present in differentiated cells) 2-fold more readily than SNAP-25a (present in both differentiated and nondifferentiated cells). Structural studies using far-ultraviolet circular dichroism (UV--CD) and thermal denaturation suggest a difference in the polypeptide folding as the underlying molecular basis for the differential sensitivity of SNAP-25b and SNAP-25a to BoNT/A cleavage. We propose differential roles for SNAP-25b and SNAP-25a in the neurotransmitter release process since our results suggest that BoNT/A inhibits neurotransmitter release by primarily cleaving SNAP-25b.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11478906     DOI: 10.1021/bi010362z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  [Use of botulinum toxin the the treatment of muscle pain].

Authors:  R Benecke; D Dressler; E Kunesch; T Probst
Journal:  Schmerz       Date:  2003-12       Impact factor: 1.107

2.  Molecular basis of activation of endopeptidase activity of botulinum neurotoxin type E.

Authors:  Roshan V Kukreja; Shashi K Sharma; Bal Ram Singh
Journal:  Biochemistry       Date:  2010-03-23       Impact factor: 3.162

Review 3.  Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.

Authors:  B R Singh
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 4.  Evidence based medicine in the use of botulinum toxin for back pain.

Authors:  B Jabbari
Journal:  J Neural Transm (Vienna)       Date:  2008-03-25       Impact factor: 3.575

5.  SNAP25 expression in mammalian retinal horizontal cells.

Authors:  Arlene A Hirano; Johann Helmut Brandstätter; Catherine W Morgans; Nicholas C Brecha
Journal:  J Comp Neurol       Date:  2011-04-01       Impact factor: 3.215

6.  Perturbation to Cholesterol at the Neuromuscular Junction Confers Botulinum Neurotoxin A Sensitivity to Neonatal Mice.

Authors:  Baskaran Thyagarajan; Joseph G Potian; Joseph J McArdle; Padmamalini Baskaran
Journal:  Toxicol Sci       Date:  2017-09-01       Impact factor: 4.849

7.  Alpha-latrotoxin rescues SNAP-25 from BoNT/A-mediated proteolysis in embryonic stem cell-derived neurons.

Authors:  Mariano Mesngon; Patrick McNutt
Journal:  Toxins (Basel)       Date:  2011-05-13       Impact factor: 4.546

8.  Characterization of clostridium botulinum neurotoxin serotype A (BoNT/A) and fibroblast growth factor receptor interactions using novel receptor dimerization assay.

Authors:  Nicholas G James; Shiazah Malik; Bethany J Sanstrum; Catherine Rhéaume; Ron S Broide; David M Jameson; Amy Brideau-Andersen; Birgitte S Jacky
Journal:  Sci Rep       Date:  2021-04-09       Impact factor: 4.379

9.  Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A).

Authors:  Birgitte P S Jacky; Patton E Garay; Jérôme Dupuy; Jeremy B Nelson; Brian Cai; Yanira Molina; Joanne Wang; Lance E Steward; Ron S Broide; Joseph Francis; K Roger Aoki; Raymond C Stevens; Ester Fernández-Salas
Journal:  PLoS Pathog       Date:  2013-05-16       Impact factor: 6.823

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.